Aytu Biopharma (AYTU) Other Accumulated Expenses (2019 - 2026)

Aytu Biopharma (AYTU) has 8 years of Other Accumulated Expenses data on file, last reported at $2.2 million in Q1 2026.

• Other Accumulated Expenses for Q1 2026 came in at $2.2 million, up 18.99% year-over-year; the trailing twelve-month figure through Mar 2026 was $2.2 million (up 18.99% YoY), and the FY2025 annual result was $3.4 million, down 62.3% from the prior year.
• Other Accumulated Expenses eased to $2.2 million in Q1 2026 per AYTU's latest filing, from $2.9 million in the prior quarter.
• Over five years, Other Accumulated Expenses peaked at $9.0 million in Q3 2023 and troughed at $221000.0 in Q3 2025.
• A 5-year average of $4.2 million and a median of $3.0 million in 2024 frame the typical range for Other Accumulated Expenses.
• The sharpest annual moves came in 2024 and 2025: Other Accumulated Expenses surged 344.32% in 2024, then plunged 92.2% in 2025.
• A 5-year view of Other Accumulated Expenses shows it stood at $7.8 million in 2022, then tumbled by 67.7% to $2.5 million in 2023, then rose by 19.64% to $3.0 million in 2024, then declined by 3.44% to $2.9 million in 2025, then declined by 24.77% to $2.2 million in 2026.
• Business Quant data shows AYTU's Other Accumulated Expenses at $2.2 million in Q1 2026, $2.9 million in Q4 2025, and $221000.0 in Q3 2025.